Neuphoria Therapeutics (NASDAQ:NEUP) had its price target lowered by analysts at HC Wainwright from $21.00 to $7.00. They now have a "buy" rating on the stock.
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders [Yahoo! Finance]
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions [Yahoo! Finance]
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions